Vimarsana
Biggest News Aggregation in the World

Page 32 - Core Lab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Core Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Core Lab Today - Breaking & Trending Today

Core Lab Sees 2022 Growth in Americas, Middle East, South Atlantic - Vimarsana News

Core Lab Sees 2022 Growth in Americas, Middle East, South Atlantic

Heavily dependent on international oil and gas activity, oilfield services (OFS) firm Core Laboratories NV is engaged in a waiting game as it looks to

Core Lab Sees 2022 Growth in Americas, Middle East, South Atlantic - Vimarsana News

Core Lab Sees 2022 Growth in Americas, Middle East, South Atlantic

Heavily dependent on international oil and gas activity, oilfield services (OFS) firm Core Laboratories NV is engaged in a waiting game as it looks to

Core Laboratories (CLB) Q4 2021 Earnings Call Transcript - Vimarsana News

Core Laboratories (CLB) Q4 2021 Earnings Call Transcript

CLB earnings call for the period ending December 31, 2021.

Source: fool.com
Investegate |F. Hoffmann-La Roche Ltd Announcements | F. Hoffmann-La Roche Ltd: [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021 - Vimarsana News

Investegate |F. Hoffmann-La Roche Ltd Announcements | F. Hoffmann-La Roche Ltd: [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021

Investegate announcements from F. Hoffmann-La Roche Ltd, [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021

F. Hoffmann-La Roche Ltd: [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021 - Vimarsana News

F. Hoffmann-La Roche Ltd: [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021

Basel, 3 February 2022 Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Division sales increase 3%; continued strong demand for newly launched medicines